Logo

Immuneering Corporation

IMRX

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology… read more

Healthcare

Biotechnology

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$4.17

Price

+0.97%

$0.04

Market Cap

$151.381m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-25.0%

5y CAGR
Earnings

-$54.440m

+2.8%

1y CAGR

-1.0%

3y CAGR

-2.2%

5y CAGR
EPS

-$1.17

+7.9%

1y CAGR

+12.4%

3y CAGR

+9.2%

5y CAGR
Book Value

$206.518b

$214.810b

Assets

$8.292b

Liabilities

$3.730b

Debt
Debt to Assets

1.7%

-63.4x

Debt to EBITDA
Free Cash Flow

-$49.911m

-9.7%

1y CAGR

-1.3%

3y CAGR

-3.5%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases